The Journal of Organic Chemistry
Article
1
73% yield from 14. H NMR (500 MHz, DMSO-d6, 350 K, δ) 2.56
(1H, d, J = 12.6), 4.17 (2H,m), 4.35 (1H, t, J = 8.3), 5.12 (2H, s), 6.99
(2H, d, J = 8.7), 7.32−7.42 (7H, m); 13C NMR (125 MHz, DMSO-d6,
350 K, δ) 28.0, 28.1, 39.1, 48.5, 55.0, 55.7, 59.5, 66.6, 81.1, 114.2,
127.7, 128.1, 128.7, 129.8, 132.3, 137.3, 154.2, 159.0, 171.0, 174.4;
HPLC analysis (C18 reverse phase, 30 min, 5−95% H2O/ACN with
0.1% formic acid) tR = 17.4 min; HRMS-ESI: m/z calcd for
C26H33N2O7 (M + H)+ 485.2282, found 485.2292.
(1H, t, J = 13.2), 3.09 (1H, dd, J = 6.6, 13.5), 3.64 (1H, d, J = 13.6),
3.87 (1H, d, J = 13.6), 4.57 (1H, dd, J = 6.7, 12.8), 5.53 (2H, s), 7.40−
7.65 (5H, m), 8.10−8.48 (10H, m); 13C NMR (125 MHz, DMSO-d6,
350 K, δ) 34.1, 41.7, 48.2, 58.8, 67.8, 123.1, 123.7, 124.3, 124.4, 125.4,
125.8, 125.9, 126.9, 127.3, 127.4, 127.5, 127.9, 128.1, 128.7, 129.2,
130.4, 130.7, 130.9, 131.4, 132.2, 155.0, 168.8, 174.2; IR (neat) 1777,
1719, 1502, 1415, 1186, 1139 cm−1; [α]18 = +3.5 (MeOH); HPLC
7-Benzyl-8-tert-butyl(5S,8S)-1-[(4-methoxyphenyl)methyl)-
D
analysis (C18 reverse phase, 40 min, 5−100% H2O/ACN with 0.1%
formic acid) tR = 17.4 min; HRMS-ESI: m/z calcd for C30H24N3O4 (M
+ H)+ 490.1761, found 490.1768.
2,4-dioxo-3-phenyl-1,3,7-triazaspiro[4,4]nonane-7,8-dicarbox-
1
ylate, 16. H NMR (500 MHz, DMSO-d6, 350 K, δ) 1.36 (9H, s),
2.20 (1H, dd, J = 8.3, 13.8), 2.69 (1H, dd, J = 8.6, 13.7), 3.61 (1H, d, J
= 11.8), 3.76 (3H, s), 3.97 (1H, d, J = 11.8), 4.38 (1H, t, J = 8.4), 4.62
(2H, s), 5.09 (2H, s), 6.91 (2H, d, J = 8.7), 7.28−7.38 (7H, m), 7.42
(1H, m), 7.47−7.53 (4H, m); 13C NMR (125 MHz, CDCl3, 298K, δ)
27.8, 36.2, 42.9, 50.2, 55.3, 58.3, 66.2, 67.6, 82.1, 114.4, 125.8, 127.8,
128.1, 128.3, 128.5, 128.9, 129.1, 129.2, 129.4, 131.3, 136.1, 154.1,
154.7, 159.4, 170.8, 173.3; IR (neat) 1682, 1607, 1493, 1399, 1344,
Synthetic Procedure for Catalyst 1d. Starting from Cbz,tert-
butyl Pro4(SS) amino acid 5 (364 mg, 1.0 mmol), the synthesis of
catalyst 1d follows the same procedure as that of catalyst 1a with the
following exceptions: (1) 4-nitrobenzaldehyde substituted for
benzaldehyde in step 1; (2) after the methanol was removed by
concentration under vacuum, 10 mL of H2O was added to the residue,
and 2 drops of 2 N KOH (aq) was added to assist the dissolution of
the amino acid before adjusting the pH to 7 in step 1.
1239, 1121 cm−1; [α]18 = −4.0 (MeOH); HPLC analysis (C18
D
reverse phase, 40 min, 5−100% H2O/ACN with 0.1% formic acid) tR
= 25.9 min; HRMS-ESI: m/z calcd for C33H35N3NaO7 (M + Na)+
608.2367, found 608.2377.
(3S,5S)-1-[(Benzyloxy)carbonyl]-5-[(tert-butoxy)carbonyl]-3-
([(4-nitrophenyl)methyl]amino)pyrrolidine-3-carboxylic Acid,
1
10. Yield 439 mg, 88% crude yield in step 1; H NMR (500 MHz,
(5S,8S)-1-[(4-Methoxyphenyl)methyl]-2,4-dioxo-3-phenyl-
1,3,7-triazaspiro[4,4]nonane-8-carboxylic Acid·TFA, 1e. Yield
207 mg, 48% yield from 16; 1H NMR(500 MHz, DMSO-d6, 350 K, δ)
2.46 (1H, m), 2.80 (1H, dd, J = 6.7, 13.6), 3.57 (1H, d, J = 13.3), 3.70
(1H, d, J = 13.4), 3.76 (3H, s), 4.54 (1H, dd, J = 6.8, 12.1), 4.62 (2H,
s), 6.91 (2H, d, J = 8.7), 7.34 (2H, d, J = 8.7), 7.39−7.43 (1H, m),
7.49−7.51 (4H, d, J = 4.3); 13C NMR (125 MHz, DMSO-d6, 350 K, δ)
34.5, 42.6, 48.3, 55.6, 58.9, 67.9, 114.6, 127.1, 128.5, 129.0, 129.1,
129.8, 132.3, 154.8, 159.3, 168.6, 173.9; IR (neat) 1775, 1719, 1513,
1414, 1247, 1179, 1135 cm−1; [α]18D = +7.8 (MeOH); HPLC analysis
(C18 reverse phase, 40 min, 5−100% H2O/ACN with 0.1% formic
acid) tR = 12.2 min; HRMS-ESI: m/z calcd for C21H22N3O5 (M + H)+
396.1554, found 396.1562.
DMSO-d6, 350 K, δ) 1.37 (9H, s), 2.22 (1H, dd, J = 6.8, 13.1), 2.82
(1H, dd, J = 8.8, 13.0), 3.56 (1H, d= 11.2), 4.00−4.08 (3H, m), 4.32
(1H, t, J = 7.6), 5.10 (2H, s), 7.30−7.38 (5H, m), 7.68 (2H, d, J = 8.7),
8.19 (2H, d, J = 8.7); 13C NMR (125 MHz, DMSO-d6, 350 K, δ) 28.0,
28.1, 38.1, 48.3, 54.1, 59.3, 66.9, 81.6, 123.6, 127.8, 128.2, 128.7, 130.2,
137.1, 145.7, 147.7, 154.1, 170.6, 172.9; HPLC analysis (C18 reverse
phase, 30 min, 5−95% H2O/ACN with 0.1% formic acid) tR = 18.7
min; HRMS-ESI: m/z calcd for C25H30N3O8 (M + H)+ 500.2027,
found 500.2032.
7-Benzyl-8-tert-butyl(5S,8S)-1-[(4-nitrophenyl)methyl)-2,4-
dioxo-3-phenyl-1,3,7-triazaspiro[4,4]nonane-7,8-dicarboxy-
late, 15. 1H NMR (500 MHz, DMSO-d6, 350 K, δ) 1.34 (9H, s), 2.21
(1H, dd, J = 8.0, 13.8), 2.83 (1H, dd, J = 8.7, 13.8), 3.61 (1H, d, J =
11.9), 4.07 (1H, d, J = 11.9), 4.42 (1H, t, J = 8.3), 4.82 (2H, dd, J =
17.3, 25.4), 5.09 (2H, s), 7.30−7.34 (5H, m), 7.42 (1H, m), 7.48−7.56
(4H, m), 7.68 (2H, d, J = 8.8), 8.19 (2H, d, J = 8.8); 13C NMR (125
MHz, CDCl3, 298K, δ) 27.8, 37.3, 42.8, 51.6, 58.4, 66.8, 67.8, 82.6,
124.1, 125.7, 128.0, 128.3, 128.5, 129.2, 131.1, 135.8, 144.3, 147.6,
154.1, 154.9, 171.0, 172.7; IR (neat) 1704, 1596, 1516, 1493, 1402,
Synthetic Procedure for Catalyst 2a. The synthesis of catalyst
2a follows the same procedure as that of catalyst 1a with the change of
beginning with Cbz,tert-butyl Pro4(SR) amino acid 6 (364 mg, 1.0
mmol) rather than Cbz,tert-butyl Pro4(SS) amino acid 5.
(3R,5S)-3-(Benzylamino)-1-[(benzyloxy)carbonyl]-5-[(tert-
butoxy)carbonyl]pyrrolidine-3-carboxylic Acid, 18. Yield 341
mg, 75% crude yield in step 1; 1H NMR (500 MHz, DMSO-d6, 350 K,
δ) 1.38 (9H, s), 2.58 (1H, dd, J = 5.6, 14.1), 2.88 (1H, t, J = 9.0), 3.84
(1H, d, J = 12.5), 4.07−4.16 (3H, m), 4.51 (1H, t, J = 6.7), 5.11 (2H,
s), 7.30−7.48 (10H, m); 13C NMR (125 MHz, DMSO-d6, 350 K, δ)
28.1, 28.2, 39.0, 48.4, 54.7, 59.5, 66.7, 81.2, 127.1, 127.8, 128.1, 128.3,
128.5, 128.7, 137.3, 140.8, 154.5, 171.2, 173.5; HPLC analysis (C18
reverse phase, 40 min, 5−100% H2O/ACN with 0.1% formic acid) tR
= 16.5 min; HRMS-ESI: m/z calcd for C25H31N2O6 (M + H)+
455.2177, found 455.2181.
7-Benzyl-8-tert-butyl(5R,8S)-1-benzyl-2,4-dioxo-3-phenyl-
1,3,7-triazaspiro[4,4]nonane-7,8-dicarboxylate, 20. 1H NMR
(500 MHz, DMSO-d6, 350 K, δ) 1.37 (9H, s), 2.40 (1H, dd, J =
6.9, 14.6), 2.77 (1H, dd, J = 9.4, 14.3), 3.63 (1H, d, J = 12.1), 3.86
(1H, d, J = 11.0), 4.35 (1H, broad), 4.60 (2H, broad), 5.05 (1H, d, J =
12,1), 7.28−7.35 (11H, m), 7.50 (4H, d, J = 4.4); 1H NMR(500 MHz,
CDCl3, 298K, δ, rotamersobserved): 1.37−1.45 (9H, d), 2.41−2.62
(2H, m), 3.76 (0.5H, d, J = 11.8), 3.87 (0.5H, dd, J = 11.8), 3.91
(0.5H, d, J = 12.1), 3.99 (0.5H, d, J = 12.1), 4.14 (0.5H, dd, J = 6.8,
9.3), 4.43−4.51 (1.5H, m), 4.76 (0.5H, d, J = 15.8), 4.84 (0.5H, d, J =
15.8), 4.92 (0.5H, d, J = 12.2), 5.11 (0.5H, d, J = 12.2), 5.17 (1H, tt, J
= 12.5), 7.23−7.53 (15H, m); 13C NMR (125 MHz, CDCl3, 298K, δ)
27.8, 27.9, 38.6, (29.9, 44.5, 54.6, 58.9, 59.5, 67.5, 68.4, 69.3, 82.5,
125.8, 127.5, 127.6, 128.0, 128.1, 128.2, 128.3, 128.5, 128.6, 128.9,
129.1, 131.5, 135.9, 136.0, 136.6, 136.7, 153.4, 153.7, 154.7, 154.8,
169.6, 169.8, 171.0, 171.3; IR (neat) 1702, 1492, 1406, 1353, 1139
cm−1; [α]18D = −88.1 (MeOH); HPLC analysis (C18 reverse phase, 40
min, 5−100% H2O/ACN with 0.1% formic acid) tR = 25.9 min;
HRMS-ESI: m/z calcd for C32H33N3NaO6 (M + Na)+ 578.2262, found
578.2267.
1340, 1125 cm−1; [α]18 = +0.75 (MeOH); HPLC analysis (C18
reverse phase, 40 min, 5−100% H2O/ACN with 0.1% formic acid) tR
= 25.8 min; HRMS-ESI: m/z calcd for C32H32N4NaO8 (M + Na)+
623.2112, found 623.2111.
D
(5S,8S)-1-[(4-Nitrophenyl)methyl]-2,4-dioxo-3-phenyl-1,3,7-
triazaspiro[4,4]nonane-8-carboxylic Acid·TFA, 1d. Yield 290 mg,
1
63% yield from 15; H NMR (500 MHz, DMSO-d6, 350 K, δ) 2.43
(1H, t, J = 13.2), 2.95 (1H, dd, J = 6.6, 13.5), 3.51 (1H, d, J = 13.6),
3.74 (1H, d, J = 13.5), 4.53 (1H, dd, J = 6.6, 12.8), 4.87 (2H, s), 7.41−
7.54 (5H, m), 7.72 (2H, d, J = 8.8), 8.24 (2H, d, J = 8.8); 13C NMR
(125 MHz, DMSO, 350 K, δ) 34.1, 42.6, 48.3, 58.7, 67.5, 124.0, 127.2,
128.3, 128.7, 129.2, 132.0, 145.9, 147.2, 154.9, 168.7, 173.9; IR (neat)
1777, 1718, 1517, 1413, 1345 cm−1; [α]18 = +1.1 (MeOH); HPLC
D
analysis (C18 reverse phase, 40 min, 5−100% H2O/ACN with 0.1%
formic acid) tR = 12.7 min; HR-MS (M + H)+ Calculated for
+
C20H19N4O6 : 411.1299; found: 411.1303.
Synthetic Procedure for Catalyst 1e. Starting from Cbz,tert-
butyl Pro4(SS) amino acid 5 (364 mg, 1.0 mmol), the synthesis of
catalyst 1e follows the same procedure as that of catalyst 1a with the
following changes: (1) 4-methoxybenzaldehyde substituted for
benzaldehyde in step 1; (2) after the methanol was removed by
concentration under vacuum, 10 mL of H2O was added to the residue,
and 2 drops of 2 N KOH (aq) was added to assist the dissolution of
the amino acid before adjusting the pH to 7 in step 1.
(3S,5S)-1-[(Benzyloxy)carbonyl]-5-[(tert-butoxy)carbonyl]-3-
([(4-methoxyphenyl)methyl]amino)pyrrolidine-3-carboxylic
1
Acid, 11. Yield 411 mg, 85% crude yield in step 1; H NMR (500
MHz, DMSO-d6, 350 K, δ) 1.40 (9H, s), 2.38 (1H, dd, J = 8.6, 13.3),
2.92 (1H, dd, J = 8.4, 13.2), 3.72 (1H, d, J = 11.4), 3.79 (3H, s), 4.10
4789
dx.doi.org/10.1021/jo300569c | J. Org. Chem. 2012, 77, 4784−4792